-
2026-05-12
Forge Ahead with a New Chapter: Nuance Pharma Beijing Headquarters Grand Opening Ceremony Celebrated in Changping
-
2026-04-21
Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal
-
2026-03-12
Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China
-
2026-01-27
Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chronic obstructive pulmonary disease
-
2025-06-25
Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD
-
2025-02-07
Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China
-
2024-09-11
Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD
Nuance Pharma announced it has completed the recruitment of patients for the ENHANCE-CHINA study, after planned number of patients have been successfully enrolled.
-
2024-08-14
PharmaBoardroom Interview with Nuance Pharma founder & CEO Mark Lotter
From a demographic and disease profile perspective, Asia-Pacific shares more similarities with China than with Western markets. This alignment makes expanding into Asia-Pacific a logical step.
Contact PR
